Table 3.
Markers | Antibodies | Cases examined ( n ) | Lining cells (na, %b) | Round cells (na, %b) |
---|---|---|---|---|
Epithelial markers |
EMA |
12 |
12 (100.00%) |
12 (100.00%) |
|
PCK |
7 |
7 (100.00%) |
0 (0.00%) |
|
CK |
5 |
5 (100.00%) |
0 (0.00%) |
|
CK-7 |
8 |
8 (100.00%) |
2 (25.00%) |
|
TTF-1 |
10 |
10 (100.00%) |
10 (100.00%) |
Neuroendocrine markers |
Syn |
7 |
0 (0.00%) |
0 (0.00%) |
|
CgA |
6 |
0 (0.00%) |
0 (0.00%) |
|
S-100 |
6 |
0 (0.00%) |
0 (0.00%) |
|
NSE |
3 |
0 (0.00%) |
0 (0.00%) |
Vascular-endothelial markers |
CD34 |
3 |
1 (33.33%) |
0 (0.00%) |
Myoepithelial markers |
Desmin |
1 |
0 (0.00%) |
0 (0.00%) |
Proliferation markers | Ki-67 | 4 | 0 (0.00%) | 4 (100.00%)c |
aNumber of cases revealing positive results.
bProportion of positive cases to the whole examined ones.
cThe expression of Ki-67 in all positive cases was <5%.